MedTrace Logo

The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer

NCT03416478 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-02-01

No results posted yet for this study

Summary

This study is to evaluate circulating tumor DNA (ctDNA) as a predictive and surveillant method for tumor recurrence in stage II and III colorectal cancer (CRC).

Conditions

Interventions

DIAGNOSTIC_TEST

ctDNA test

ctDNA test to find some possible mutation.

Sponsors & Collaborators

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xiaojian Wu, MD, PhD · Sixth Affiliated Hospital, Sun Yet-sen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03416478 on ClinicalTrials.gov